ǂan ǂinternational multicenter study
Luka Brčić (Avtor), Thomas Klikovits (Avtor), Zsolt Megyesfalvi (Avtor), Berta Mosleh (Avtor), Katharina Sinn (Avtor), Richard Hritcu (Avtor), Viktoria Laszlo (Avtor), Tanja Čufer (Avtor), Aleš Rozman (Avtor), Izidor Kern (Avtor), Katja Mohorčič (Avtor)

Povzetek

Background: Programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) immune-checkpoint blockade is a promising new therapeutic strategy in cancer. However, expression patterns and prognostic significance of PD-L1 and PD-1 are still controversial in human malignant pleural mesothelioma (MPM). Methods: Formalin-fixed paraffin-embedded (FFPE) tumor samples from 203 MPM patients receiving standard treatment without immunotherapy were collected from 5 European centers. PD-L1 and PD-1 expression of tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs) were measured by immunohistochemistry and correlated with clinical parameters and long-term outcome. Results: High (>10%) PD-L1 TC and PD-1 TILs expressions were found in 18 (8%) and 39 (24%) patients, respectively. PD-L1 was rarely expressed by TILs [>/=1%, n=13 (8%); >10%, n=1]. No significant associations were found between the PD-L1 or PD-1 expression of TCs or TILs and clinicopathological parameters such as stage or histological subtype. Notably, patients with high (>10%) TC-specific PD-L1 expression exhibited significantly worse median overall survival (OS) (6.3 vs. 15.1 months of those with low TC PD-L1 expression; HR: 2.51, P<0.001). In multivariate cox regression analysis adjusted for clinical parameters, high TC PD-L1 expression (>10%) proved to be an independent negative prognostic factor for OS (HR: 2.486, P=0.005). There was no significant correlation between PD-L1 or PD-1 expression of TILs and OS. Conclusions: In this multicenter cohort study, we demonstrate that high (>10%) PD-L1 expression of TCs independently predicts worse OS in MPM. Further studies are warranted to investigate the value of PD-L1/PD-1 expression as a marker for treatment response in MPM patients receiving immunotherapy.

Ključne besede

maligni plevralni mezoteliom;ligand programirane celične smrti 1;programirana celična smrt 1;PD-L1;malignant pleural mesothelioma;programmed death-ligand 1;programmed cell death 1;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Založnik: AME Publishing
UDK: 616-006
COBISS: 56719619 Povezava se bo odprla v novem oknu
ISSN: 2226-4477
Št. ogledov: 690
Št. prenosov: 324
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarne ključne besede: Mesothelioma;Anatomy and histology;Analysis;Prognosis;Mezoteliom;Anatomija in histologija;Analiza;Prognoza;
Komentar vira: Nasl. z nasl. zaslona; Soavtorji iz Slovenije: Tanja Cufer, Ales Rozman, Izidor Kern, Katja Mohorcic; Opis vira z dne 22. 3. 2021;
Strani: str. 1594-1607
Letnik: ǂVol. ǂ10
Zvezek: ǂno. ǂ4
Čas izdaje: Apr. 2021
DOI: 10.21037/tlcr-20-1114
ID: 12712890